{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,8]],"date-time":"2022-04-08T21:12:21Z","timestamp":1649452341553},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2014,6,17]],"date-time":"2014-06-17T00:00:00Z","timestamp":1402963200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Am J Clin Dermatol"],"published-print":{"date-parts":[[2014,10]]},"DOI":"10.1007\/s40257-014-0084-6","type":"journal-article","created":{"date-parts":[[2014,6,19]],"date-time":"2014-06-19T07:35:34Z","timestamp":1403163334000},"page":"451-456","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Interferon-Based Treatment for Patients with Mycosis Fungoides and Hepatitis\u00a0C Virus Infection: A\u00a0Case Series"],"prefix":"10.1007","volume":"15","author":[{"given":"Andreas","family":"Kyvernitakis","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Madeleine","family":"Duvic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Parag","family":"Mahale","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Harrys A.","family":"Torres","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2014,6,17]]},"reference":[{"issue":"20","key":"84_CR1","doi-asserted-by":"crossref","first-page":"4337","DOI":"10.1182\/blood-2009-07-202895","volume":"114","author":"HM Prince","year":"2009","unstructured":"Prince HM, Whittaker S, Hoppe RT. How I treat mycosis fungoides and Sezary syndrome. Blood. 2009;114(20):4337\u201353.","journal-title":"Blood"},{"issue":"3","key":"84_CR2","doi-asserted-by":"crossref","first-page":"193","DOI":"10.2165\/00128071-200203030-00006","volume":"3","author":"N Apisarnthanarax","year":"2002","unstructured":"Apisarnthanarax N, Talpur R, Duvic M. Treatment of cutaneous T\u00a0cell lymphoma: current status and future directions. Am J Clin Dermatol. 2002;3(3):193\u2013215.","journal-title":"Am J Clin Dermatol"},{"key":"84_CR3","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1007\/978-1-62703-408-1_19","volume-title":"Lymphoma: diagnosis and treatment","author":"M Duvic","year":"2013","unstructured":"Duvic M. Cutaneous T-cell lymphomas: mycosis fungoides and S\u00e9zary syndrome. In: Younes A, Coiffier B, editors. Lymphoma: diagnosis and treatment. 43rd ed. Totowa: Humana Press; 2013. p. 287\u2013321.","edition":"43"},{"issue":"4","key":"84_CR4","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1002\/hep.24641","volume":"54","author":"MG Ghany","year":"2011","unstructured":"Ghany MG, Nelson DR, Strader DB, Thomas DL, Seeff LB. An update on treatment of genotype\u00a01 chronic hepatitis\u00a0C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology. 2011;54(4):1433\u201344.","journal-title":"Hepatology"},{"issue":"11","key":"84_CR5","doi-asserted-by":"crossref","first-page":"2771","DOI":"10.3748\/wjg.v20.i11.2771","volume":"20","author":"RA Borchardt","year":"2014","unstructured":"Borchardt RA, Torres HA. Challenges in managing hepatitis\u00a0C virus infection in cancer patients. World J Gastroenterol. 2014;20(11):2771\u20136.","journal-title":"World J Gastroenterol"},{"issue":"4","key":"84_CR6","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1002\/hep.23444","volume":"51","author":"M Martinot-Peignoux","year":"2010","unstructured":"Martinot-Peignoux M, Stern C, Maylin S, et al. Twelve weeks posttreatment follow-up is as relevant as 24\u00a0weeks to determine the sustained virologic response in patients with hepatitis\u00a0C virus receiving pegylated interferon and ribavirin. Hepatology. 2010;51(4):1122\u20136.","journal-title":"Hepatology"},{"issue":"18","key":"84_CR7","doi-asserted-by":"crossref","first-page":"2598","DOI":"10.1200\/JCO.2010.32.0630","volume":"29","author":"EA Olsen","year":"2011","unstructured":"Olsen EA, Whittaker S, Kim YH, et al. Clinical end points and response criteria in mycosis fungoides and Sezary syndrome: a consensus statement of the International Society for Cutaneous Lymphomas, the United States Cutaneous Lymphoma Consortium, and the Cutaneous Lymphoma Task Force of the European Organisation for Research and Treatment of Cancer. J Clin Oncol. 2011;29(18):2598\u2013607.","journal-title":"J Clin Oncol"},{"key":"84_CR8","volume-title":"Division of AIDS table for grading the severity of adult and pediatric adverse events","author":"Division of AIDS","year":"2004","unstructured":"Division of AIDS. Division of AIDS table for grading the severity of adult and pediatric adverse events. Bethesda: Division of AIDS; 2004."},{"issue":"2","key":"84_CR9","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1097\/00042737-200402000-00003","volume":"16","author":"JP Gisbert","year":"2004","unstructured":"Gisbert JP, Garcia-Buey L, Arranz R, et al. The prevalence of hepatitis\u00a0C virus infection in patients with non-Hodgkin\u2019s lymphoma. Eur J Gastroenterol Hepatol. 2004;16(2):135\u20138.","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"4","key":"84_CR10","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1093\/infdis\/jis385","volume":"206","author":"MH Lee","year":"2012","unstructured":"Lee MH, Yang HI, Lu SN, et al. Chronic hepatitis\u00a0C virus infection increases mortality from hepatic and extrahepatic diseases: a community-based long-term prospective study. J Infect Dis. 2012;206(4):469\u201377.","journal-title":"J Infect Dis"},{"issue":"3","key":"84_CR11","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1002\/hep.20608","volume":"41","author":"AS Duberg","year":"2005","unstructured":"Duberg AS, Nordstrom M, Torner A, et al. Non-Hodgkin\u2019s lymphoma and other nonhepatic malignancies in Swedish patients with hepatitis\u00a0C virus infection. Hepatology. 2005;41(3):652\u20139.","journal-title":"Hepatology"},{"issue":"7","key":"84_CR12","doi-asserted-by":"crossref","first-page":"2385","DOI":"10.1182\/blood.V88.7.2385.bloodjournal8872385","volume":"88","author":"E Diamandidou","year":"1996","unstructured":"Diamandidou E, Cohen PR, Kurzrock R. Mycosis fungoides and Sezary syndrome. Blood. 1996;88(7):2385\u2013409.","journal-title":"Blood"},{"issue":"5","key":"84_CR13","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1111\/j.1365-2133.2004.06268.x","volume":"151","author":"S Miertusova","year":"2004","unstructured":"Miertusova S, Bonin S, Trevisan G, Stanta G. Mycosis fungoides is not associated with hepatitis\u00a0C virus infection. Br J Dermatol. 2004;151(5):1108\u201310.","journal-title":"Br J Dermatol"},{"issue":"3","key":"84_CR14","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1200\/JCO.2005.06.008","volume":"23","author":"D Vallisa","year":"2005","unstructured":"Vallisa D, Bernuzzi P, Arcaini L, et al. Role of anti-hepatitis\u00a0C virus (HCV) treatment in HCV-related, low-grade, B-cell, non-Hodgkin\u2019s lymphoma: a multicenter Italian experience. J Clin Oncol. 2005;23(3):468\u201373.","journal-title":"J Clin Oncol"},{"key":"84_CR15","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/1471-2210-10-15","volume":"10","author":"I Garcia-Garcia","year":"2010","unstructured":"Garcia-Garcia I, Gonzalez-Delgado CA, Valenzuela-Silva CM, et al. Pharmacokinetic and pharmacodynamic comparison of two \u201cpegylated\u201d interferon alpha-2 formulations in healthy male volunteers: a randomized, crossover, double-blind study. BMC Pharmacol. 2010;10:15.","journal-title":"BMC Pharmacol"},{"issue":"S4","key":"84_CR16","first-page":"909A","volume":"58","author":"P Mahale","year":"2013","unstructured":"Mahale P, Miller ED, Blechacz B, Herlong HF, Davila M, Torres HA. The effect of antiviral therapy on progression of liver disease in hepatitis\u00a0C virus-infected patients with malignancies. Hepatology. 2013;58(S4):909A.","journal-title":"Hepatology"},{"issue":"19","key":"84_CR17","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1093\/jnci\/91.19.1616","volume":"91","author":"JE Groopman","year":"1999","unstructured":"Groopman JE, Itri LM. Chemotherapy-induced anemia in adults: incidence and treatment. J Natl Cancer Inst. 1999;91(19):1616\u201334.","journal-title":"J Natl Cancer Inst"},{"issue":"9","key":"84_CR18","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1136\/gut.2005.076646","volume":"55","author":"MP Manns","year":"2006","unstructured":"Manns MP, Wedemeyer H, Cornberg M. Treating viral hepatitis\u00a0C: efficacy, side effects, and complications. Gut. 2006;55(9):1350\u20139.","journal-title":"Gut"},{"issue":"8","key":"84_CR19","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.5858\/2007-131-1281-TCFBMR","volume":"131","author":"F Khalil","year":"2007","unstructured":"Khalil F, Cualing H, Cogburn J, Miles L. The criteria for bone marrow recovery post-myelosuppressive therapy for acute myelogenous leukemia: a quantitative study. Arch Pathol Lab Med. 2007;131(8):1281\u20139.","journal-title":"Arch Pathol Lab Med"},{"key":"84_CR20","unstructured":"American Association for the Study of Liver Diseases, Infectious Diseases Society of America, International Antiviral Society\u2013USA. Initial treatment of HCV infection in patients starting treatment. Recommendations for testing, managing, and treating hepatitis\u00a0C. 2014. http:\/\/www.hcvguidelines.org . Accessed 27 May 2014."},{"issue":"21","key":"84_CR21","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.1056\/NEJMoa1402338","volume":"370","author":"P Ferenci","year":"2014","unstructured":"Ferenci P, Bernstein D, Lalezari J, et al. ABT-450\/rombitasvir and dasabuvir with or without ribavirin for HCV. N Engl J Med. 2014;370(21):1983\u201392.","journal-title":"N Engl J Med"},{"issue":"3","key":"84_CR22","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1056\/NEJMoa1306218","volume":"370","author":"MS Sulkowski","year":"2014","unstructured":"Sulkowski MS, Gardiner DF, Rodriguez-Torres M, et al. Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. N Engl J Med. 2014;370(3):211\u201321.","journal-title":"N Engl J Med"},{"issue":"S4","key":"84_CR23","first-page":"1290A","volume":"58","author":"HA Torres","year":"2013","unstructured":"Torres HA, Mahale P, Raad II, Kontoyannis DP. Hepatitis\u00a0C virus infection in patients with cancer: a single-institution experience in 642 patients. Hepatology. 2013;58(S4):1290A.","journal-title":"Hepatology"},{"issue":"7","key":"84_CR24","first-page":"825","volume":"12","author":"J Makdisi","year":"2013","unstructured":"Makdisi J, Friedman A. Myocosis fungoides\u2014an update on a non-mycotic disease. J Drugs Dermatol. 2013;12(7):825\u201331.","journal-title":"J Drugs Dermatol"},{"issue":"5","key":"84_CR25","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1001\/archderm.142.5.649","volume":"142","author":"T Yanagi","year":"2006","unstructured":"Yanagi T, Shimizu T, Ujiie H, et al. Peginterferon alfa-2b for mycosis fungoides. Arch Dermatol. 2006;142(5):649\u201351.","journal-title":"Arch Dermatol"},{"issue":"1","key":"84_CR26","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1002\/emmm.201303131","volume":"6","author":"CM Lange","year":"2014","unstructured":"Lange CM, Jacobson IM, Rice CM, Zeuzem S. Emerging therapies for the treatment of hepatitis\u00a0C. EMBO Mol Med. 2014;6(1):4\u201315.","journal-title":"EMBO Mol Med"},{"issue":"1","key":"84_CR27","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1007\/s11894-012-0305-1","volume":"15","author":"JN Gaetano","year":"2013","unstructured":"Gaetano JN, Reau N. Hepatitis\u00a0C: management of side effects in the era of direct-acting antivirals. Curr Gastroenterol Rep. 2013;15(1):305.","journal-title":"Curr Gastroenterol Rep"}],"container-title":["American Journal of Clinical Dermatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40257-014-0084-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40257-014-0084-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40257-014-0084-6","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,8]],"date-time":"2022-04-08T20:35:59Z","timestamp":1649450159000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40257-014-0084-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,6,17]]},"references-count":27,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2014,10]]}},"alternative-id":["84"],"URL":"https:\/\/doi.org\/10.1007\/s40257-014-0084-6","relation":{},"ISSN":["1175-0561","1179-1888"],"issn-type":[{"value":"1175-0561","type":"print"},{"value":"1179-1888","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,6,17]]}}}